The Department of War is required to establish an integrated pharmacy benefits program for the Military Health System, involving the selection of pharmaceutical agents for the Uniform Formulary based on clinical and cost effectiveness. A Request for Quotation has been issued for drug classes under review, with potential awards of Uniform Formulary Blanket Purchase Agreements and Additional Discount Program Agreements. The Pharmacy and Therapeutics Committee will meet in August 2026 to review newly approved drugs, including Atoncy, Baxfendy, Duloxetine, Filkri, Hepcludex, Lynavoy, Veppanu, Xocova, and Xtoro. A pre-quotation teleconference is scheduled for July 15, 2026, with clinical question responses due by a specified date. Performance location and budget amounts are not specified in the description.

The Department of War is required to establish an integrated pharmacy benefits program for the Military Health System, involving the selection of pharmaceutical agents for the Uniform Formulary (UF) based on clinical and cost effectiveness. A Request for Quotation (RFQ) has been issued for drug classes under review, with potential awards of Uniform Formulary Blanket Purchase Agreements (UF BPA) and Additional Discount Program Agreements (UF ADP). The P&T Committee will review several newly approved drugs in August 2026, including agents for ADHD, diuretics, antidepressants, and other conditions. A pre-quotation teleconference is scheduled for July 15, 2026, with details provided in the RFQ. Performance location and specific budget amounts are not specified in the description.